A Multicentre, Retrospective Chart Review Study to Describe the Clinical Profile of Idiopathic Pulmonary Fibrosis (IPF) Patients Treated With Nintedanib (OFEV®) in Real-world Practice in Spain.
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 01 Dec 2017
At a glance
- Drugs Nintedanib (Primary) ; Antineoplastics; Protein kinase inhibitors
- Indications Idiopathic pulmonary fibrosis
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 28 Nov 2017 Status changed from recruiting to active, no longer recruiting.
- 27 Oct 2017 Planned End Date changed from 29 Dec 2017 to 31 Jan 2018.
- 27 Oct 2017 Planned primary completion date changed from 29 Dec 2017 to 31 Jan 2018.